Peter Zdziarski: Increasing Investment Activity, Data Generation, and Implications for Patient Access to Glanzmann Thrombasthenia
Peter Zdziarski, Founder and Marketing Director of Glanzmann Thrombasthenia Advocacy Network, shared a post on LinkedIn:
“I always track what’s trending with Glanzmann Thrombasthenia so I can keep our community informed on the latest studies, news, and research.
Lately, a lot of what I’m seeing is centered around multiple companies in the space going public or moving in that direction.
On one side, that’s exciting. More investment can move research forward.
But it can also bring pressure to show growth.
In GT, that can mean more data collection, more sponsored content targeting our community, and stronger attempts to shape the narrative toward the negatives of living with a rare disease.
There’s also the concern around pricing. When new treatments do come, will access be prioritized, or will profits?
Of course, I hope I’m wrong. And I hope to start seeing more stories of patients living, adapting, and succeeding trending again soon for GT.”
More posts featuring Peter Zdziarski on Hemostasis Today.
-
Jun 24, 2026, 09:29Advancing Women’s Health Through Collaboration with Jean Hailes for Women’s Health – Stroke Foundation
-
Jun 24, 2026, 09:18The Lasting Immunological Footprint of VITT – JTH
-
Jun 24, 2026, 09:09Umberto Pensato: Dedicated Funding Pathways for Stroke Research in Italy
-
Jun 24, 2026, 09:00Danny Gaskin: BBTS 2026 and the Evolving Role of Transfusion in Maternity Care
-
Jun 24, 2026, 07:46Wolfgang Miesbach: WFH’s First AAV Gene Therapy Chapter Marks a New Era in Hemophilia Care
-
Jun 24, 2026, 06:42Deepthi Krishna: World Blood Donor Day 2026 Celebrations at Rela Hospital
-
Jun 24, 2026, 03:36Ana Pedrero Gil: A New Approach to Post-Tonsillectomy Hemorrhage
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting